Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05574673 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

Study acronym: HERO
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment target: 350 to 1000v5 Show 4 more changesShow less
    • Primary completion date: Dec 1, 2028 to May 1, 2028
    • Study completion date: Dec 1, 2028 to Jul 1, 2032
    • Secondary endpoints: details revised at 6 of 6 entries
    • Study description expanded, about 69 words
  2. Re-verified, no change to tracked fieldsv4
  3. Enrollment target: 300 to 350v3 Show 5 more changesShow less
    • Primary and study completion dates: Oct 30, 2028 to Dec 1, 2028
    • Eligibility criteria shortened, about 51 words
    • Study description expanded, about 32 words
    • Site contact updated
    • Study title revised
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
Trial Details
NCT Number NCT05574673
Lead Sponsor Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Conditions
(from sponsor)		 Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Related terms Fallopian Tube Neoplasms, Kenny-Caffey syndrome, Type 1, Ovarian Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov